Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472887 · ClinicalTrials.gov registry record · Phase 2
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT01472887: Completed Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Sanofi.
NCT01472887 is a Phase 2 study of Diffuse Large B Cell Lymphoma that has completed, run by Sanofi. The registered enrollment target is 61 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01472887, a Phase 2 study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: Participants achieving an Objective Response Rate Secondary Objective: * Progression Free Survival * Overall Survival * Response Duration * Safety
Conditions Studied
Interventions
- DRUG SAR3419
Study Locations (20)
Other
- Investigational Site Number 056002 - Ghent
- Investigational Site Number 056001 - Leuven
- Investigational Site Number 203002 - Brno
- Investigational Site Number 203003 - Prague
- Investigational Site Number 203001 - Prague
- Investigational Site Number 376003 - Jerusalem
- Investigational Site Number 376002 - Tel Litwinsky
- Investigational Site Number 380002 - Bergamo
- Investigational Site Number 380004 - Bologna
- Investigational Site Number 380008 - Mestre
- Investigational Site Number 380001 - Milan
- Investigational Site Number 380007 - Modena
- Investigational Site Number 380003 - Palermo
- Investigational Site Number 380006 - Pavia
- Investigational Site Number 616003 - Brzozów
- Investigational Site Number 616002 - Kielce
- Investigational Site Number 616001 - Warsaw
Colorado
- Investigational Site Number 840001 - Denver
Georgia
- Investigational Site Number 840003 - Augusta
Idaho
- Investigational Site Number 840005 - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT01472887 record still lists
NCT01472887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SAR3419 is the first listed.
NCT01472887 names 20 study sites across 4 states, led by Other, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT01472887 about?
NCT01472887 is a clinical study titled "SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients". Primary Objective: Participants achieving an Objective Response Rate Secondary Objective: * Progression Free Survival * Overall Survival * Response Duration * Safety
What is the current status of trial NCT01472887?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2012-01. Estimated completion is 2016-09.
What conditions does trial NCT01472887 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT01472887?
The interventions under investigation include: SAR3419 (DRUG).
Who is sponsoring clinical trial NCT01472887?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01472887 being conducted?
This trial has 20 study locations across Colorado, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01472887's enrollment target sits among peer trials
61 53rd of 114 higher than 62 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia